These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16148447)

  • 1. Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors.
    Moreno M; Escuredo L; Muñoz R; Rodriguez de Fonseca F; Navarro M
    Behav Pharmacol; 2005 Sep; 16(5-6):423-30. PubMed ID: 16148447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
    Järbe TU; DiPatrizio NV
    Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.
    Ottani A; Leone S; Sandrini M; Ferrari A; Bertolini A
    Eur J Pharmacol; 2006 Feb; 531(1-3):280-1. PubMed ID: 16438952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids modulate ultrasound-induced aversive responses in rats.
    Finn DP; Jhaveri MD; Beckett SR; Kendall DA; Marsden CA; Chapman V
    Psychopharmacology (Berl); 2004 Feb; 172(1):41-51. PubMed ID: 14634713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.
    Wiskerke J; Stoop N; Schetters D; Schoffelmeer AN; Pattij T
    PLoS One; 2011; 6(10):e25856. PubMed ID: 22016780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
    Manzanares J; Corchero J; Fuentes JA
    Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
    Cippitelli A; Bilbao A; Hansson AC; del Arco I; Sommer W; Heilig M; Massi M; Bermúdez-Silva FJ; Navarro M; Ciccocioppo R; de Fonseca FR;
    Eur J Neurosci; 2005 Apr; 21(8):2243-51. PubMed ID: 15869521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
    McMahon LR; Amin MR; France CP
    Behav Pharmacol; 2005 Sep; 16(5-6):363-72. PubMed ID: 16148440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents.
    Wade MR; Degroot A; Nomikos GG
    Eur J Pharmacol; 2006 Dec; 551(1-3):162-7. PubMed ID: 17030030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
    Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
    Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice.
    Rodgers RJ; Evans PM; Murphy A
    Behav Pharmacol; 2005 Sep; 16(5-6):405-13. PubMed ID: 16148445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
    Katsidoni V; Kastellakis A; Panagis G
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.
    Forget B; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2005 Oct; 181(4):722-34. PubMed ID: 15986197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol.
    Economidou D; Mattioli L; Ubaldi M; Lourdusamy A; Soverchia L; Hardiman G; Campolongo P; Cuomo V; Ciccocioppo R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):73-85. PubMed ID: 17618662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats.
    Moreno M; Lopez-Moreno JA; Rodríguez de Fonseca F; Navarro M
    Behav Pharmacol; 2005 Sep; 16(5-6):441-6. PubMed ID: 16148449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
    Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.
    Hill MN; Froese LM; Morrish AC; Sun JC; Floresco SB
    Psychopharmacology (Berl); 2006 Aug; 187(2):245-59. PubMed ID: 16752140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.